BR9910119A - Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina - Google Patents

Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina

Info

Publication number
BR9910119A
BR9910119A BR9910119-0A BR9910119A BR9910119A BR 9910119 A BR9910119 A BR 9910119A BR 9910119 A BR9910119 A BR 9910119A BR 9910119 A BR9910119 A BR 9910119A
Authority
BR
Brazil
Prior art keywords
alanine
beta
heterocyclic derivatives
glycyl
vitronectin antagonists
Prior art date
Application number
BR9910119-0A
Other languages
English (en)
Inventor
Nizal Samuel Chandrakumar
Bipinchandra Nanubhai Desai
Balekudru Devadas
Renne Huff
Ish K Khanna
Shashidhar N Rao
Joseph G Rico
Thomas E Rogers
Peter G Ruminski
Mark Andrew Russell
Yi Yu
Alan Frank Gasiecki
James W Malecha
Julie M Miyashiro
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9910119A publication Critical patent/BR9910119A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS HETEROCìCLICOS DE GLICIL BETA-ALANINA COMO ANTAGONISTAS DE VITRONECTINA"<D>. A presente invenção se refere a uma classe de compostos representados pela fórmula (l) ou sais farmaceuticamente aceitáveis dos mesmos, composições farmacêuticas contendo tais compostos e métodos de tratamento de condições doentias mediados pela integrina <244>~ v~ß~ 3~.
BR9910119-0A 1998-04-10 1999-04-09 Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina BR9910119A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8139498P 1998-04-10 1998-04-10
PCT/US1999/004297 WO1999052896A1 (en) 1998-04-10 1999-04-09 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists

Publications (1)

Publication Number Publication Date
BR9910119A true BR9910119A (pt) 2001-10-09

Family

ID=22163868

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910119-0A BR9910119A (pt) 1998-04-10 1999-04-09 Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina

Country Status (17)

Country Link
EP (1) EP1070060A1 (pt)
JP (1) JP2002511462A (pt)
KR (1) KR20010042614A (pt)
CN (1) CN1304406A (pt)
AR (1) AR015759A1 (pt)
AU (1) AU765294B2 (pt)
BR (1) BR9910119A (pt)
CA (1) CA2326665A1 (pt)
CZ (1) CZ20003672A3 (pt)
IL (1) IL138677A0 (pt)
MY (1) MY133473A (pt)
NO (1) NO20005084L (pt)
NZ (1) NZ507292A (pt)
PL (1) PL343406A1 (pt)
RU (1) RU2215746C2 (pt)
TW (1) TWI247008B (pt)
WO (1) WO1999052896A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
JP2002533416A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
HUP0200803A3 (en) * 1999-04-12 2002-12-28 Aventis Pharma Ltd West Mallin Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
MXPA01010834A (es) * 1999-04-28 2002-04-24 Basf Ag Antagonistas de los receptores para integrina.
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
AU2001268490A1 (en) 2000-06-15 2001-12-24 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003299600A1 (en) * 2002-12-20 2004-07-29 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
BRPI0817835A2 (pt) 2007-10-18 2015-03-31 Boehringer Ingelheim Int Antagonistas cgrp
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
WO2009065919A2 (de) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
CA2705599A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
WO2014015054A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
JP7220653B2 (ja) * 2016-11-08 2023-02-10 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロールアミド
CN115551846B (zh) * 2020-05-14 2024-03-08 Ｕｂｅ株式会社 1,4,5,6-四氢嘧啶-2-胺衍生物
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
CN115626912B (zh) * 2022-09-27 2024-03-26 中山大学 一种硫脲化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
ES2161373T3 (es) * 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
AU724191B2 (en) * 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
AR015759A1 (es) 2001-05-16
PL343406A1 (en) 2001-08-13
NZ507292A (en) 2003-12-19
CN1304406A (zh) 2001-07-18
KR20010042614A (ko) 2001-05-25
EP1070060A1 (en) 2001-01-24
MY133473A (en) 2007-11-30
CA2326665A1 (en) 1999-10-21
IL138677A0 (en) 2001-10-31
JP2002511462A (ja) 2002-04-16
RU2215746C2 (ru) 2003-11-10
NO20005084D0 (no) 2000-10-09
NO20005084L (no) 2000-11-27
TWI247008B (en) 2006-01-11
WO1999052896A1 (en) 1999-10-21
AU3449999A (en) 1999-11-01
CZ20003672A3 (cs) 2001-08-15
AU765294B2 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
BR9910119A (pt) Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina
FI950309A0 (fi) Proliiniamidijohdannaisia
ATE204857T1 (de) Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
DE69705829T2 (de) Meta-substituierte phenylsulphonamidderivate
DE69710319T2 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
ATE202337T1 (de) Cyclopropylalkansäurederivate
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
DK1106612T3 (da) Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
YU52000A (sh) Jedinjenja meta-azaciklične amino benzojeve kiseline i njihovi derivati, koji su antagonisti integrina
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
DE69429328D1 (de) N-(3-piperidinylcarbonyl)-b-alanin derivate als paf-antagonisten
PT992509E (pt) Novos derivados macrolidos
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina
BR9902653A (pt) Derivados de di-ou triaza-espiro [4,5] decano
BR0113671A (pt) Antagonistas de integrina alfa v beta 3 gem-substituìda
DE60332851D1 (de) Indolinverbindung und deren medizinische verwendung
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1975 DE 11/11/2008.